Document Detail

Current trends in negative immuno-synergy between two sexually transmitted infectious viruses: HIV-1 and HSV-1/2.
MedLine Citation:
PMID:  23355766     Owner:  NLM     Status:  Publisher    
In the current era of effective anti-retroviral therapy, immuno-compromised patients with HIV-1 infection do live long enough to suffer diseases caused by many opportunistic infections, such as herpes simplex virus type 1 and/or type 2 (HSV-1/2). An estimated two-third of the 40 million individuals that have contracted HIV-1 worldwide are co-infected with HSV-1/2 viruses, the causative agents of ocular oro-facial and genital herpes. The highest prevalence of HIV and HSV-1/2 infections are confined to the same regions of Sub-Saharan Africa. HSV-1/2 infections affect HIV-1 immunity, and vice versa. While important research gains have been made in understanding herpes and HIV immunity, the cellular and molecular mechanisms underlying the crosstalk between HSV-1/2 and HIV co-infection remain to be fully elucidated. Understanding the mechanisms behind the apparent HSV/HIV negative immuno-synergy maybe the key to successful HSV and HIV vaccines; both are currently unavailable. An effective herpes immunotherapeutic vaccine would in turn - indirectly - contribute in reducing HIV epidemic. The purpose of this review is: (i) to summarize the current trends in understanding the negative immuno-crosstalk between HIV and HSV-1/2 infections; and (ii) to discuss the possibility of developing a novel mucosal herpes immunotherapeutic strategy or even a combined or chimeric immunotherapeutic vaccine that simultaneously targets HIV and HSV-1/2 infections. These new trends in immunology of HSV-1/2 and HIV co-infections should become part of current efforts in preventing sexually transmitted infections. The alternative is needed to balance the ethical and financial concerns associated with the rising number of unsuccessful mono-valent clinical vaccine trials.
Aziz Alami Chentoufi; Xavier Dervillez; Pierre-Alain Rubbo; Tiffany Kuo; Xiuli Zhang; Nicolas Nagot; Edouard Tuaillon; Philippe Van De Perre; Anthony B Nesburn; Lbachir Benmohamed
Related Documents :
22234356 - Clinical and laboratory findings in patients with dengue associated with hepatopathy.
23348596 - The antimalarial ferroquine is an inhibitor of hepatitis c virus.
17136956 - A two-stage logistic model based on the measurement of pro-inflammatory cytokines in br...
7774516 - Rifaximin. a review of its antibacterial activity, pharmacokinetic properties and thera...
21145066 - Prevalence and prognostic significance of ecg abnormalities in hiv-infected patients: r...
19378646 - Multidimensional family therapy hiv/std risk-reduction intervention: an integrative fam...
Publication Detail:
Journal Detail:
Title:  Current trends in immunology     Volume:  13     ISSN:  0972-4567     ISO Abbreviation:  Curr Trends Immunol     Publication Date:  2012  
Date Detail:
Created Date:  2013-1-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101525702     Medline TA:  Curr Trends Immunol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  51-68     Citation Subset:  -    
Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, CA 92697-4375, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Temperament and Social Problem Solving Competence in Preschool: Influences on Academic Skills in Ear...
Next Document:  Selectivity Enhancement for Chloride Ion by In(III)-Porphyrin-Based Polymeric Membrane Electrode Ope...